JP2020506205A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506205A5
JP2020506205A5 JP2019542722A JP2019542722A JP2020506205A5 JP 2020506205 A5 JP2020506205 A5 JP 2020506205A5 JP 2019542722 A JP2019542722 A JP 2019542722A JP 2019542722 A JP2019542722 A JP 2019542722A JP 2020506205 A5 JP2020506205 A5 JP 2020506205A5
Authority
JP
Japan
Prior art keywords
group
alkyl
heterocyclyl
cycloalkyl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542722A
Other languages
English (en)
Japanese (ja)
Other versions
JP7049353B2 (ja
JP2020506205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052620 external-priority patent/WO2018146008A1/en
Publication of JP2020506205A publication Critical patent/JP2020506205A/ja
Publication of JP2020506205A5 publication Critical patent/JP2020506205A5/ja
Application granted granted Critical
Publication of JP7049353B2 publication Critical patent/JP7049353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542722A 2017-02-08 2018-02-02 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 Active JP7049353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155191.4 2017-02-08
EP17155191 2017-02-08
PCT/EP2018/052620 WO2018146008A1 (en) 2017-02-08 2018-02-02 Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes

Publications (3)

Publication Number Publication Date
JP2020506205A JP2020506205A (ja) 2020-02-27
JP2020506205A5 true JP2020506205A5 (enExample) 2021-01-14
JP7049353B2 JP7049353B2 (ja) 2022-04-06

Family

ID=57995116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542722A Active JP7049353B2 (ja) 2017-02-08 2018-02-02 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物

Country Status (5)

Country Link
US (1) US10550127B1 (enExample)
EP (1) EP3580222B1 (enExample)
JP (1) JP7049353B2 (enExample)
CN (1) CN110300755B (enExample)
WO (1) WO2018146008A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110312714B (zh) 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
JP7023969B2 (ja) 2017-01-26 2022-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CA3093851A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2505322A (en) 1945-09-14 1950-04-25 Gibson Refrigerator Co Refrigerator cabinet
US2560111A (en) 1946-11-07 1951-07-10 Raymond T Levine Buffing chuck
US2656003A (en) 1948-02-27 1953-10-20 Inst Of Inventive Res High explosive disk-shaped charge for seismic exploration
US2727340A (en) 1953-08-31 1955-12-20 Alfred S Zanotta Portable tool for reconditioning crane rails
US5356287A (en) 1987-03-16 1994-10-18 Mcintyre Kevin M Simulating presence
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
US7664629B2 (en) 2005-07-19 2010-02-16 Xerox Corporation Second language writing advisor
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
KR20080103584A (ko) 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
CA2727340A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
ES2345916B1 (es) 2008-10-14 2011-09-14 Clipdorfix, S.L. Dispositivo de fijacion liberable de elementos adosados.
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
HK1210144A1 (en) 2012-11-28 2016-04-15 勃林格殷格翰国际有限公司 New indanyloxydihydrobenzofuranylacetic acids
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
KR101735787B1 (ko) 2013-02-28 2017-05-16 주식회사 티움바이오 삼환식 화합물 및 이의 용도
EP3036237A4 (en) 2013-08-23 2017-01-25 Fujian Haixi Pharmaceuticals Co. Ltd Carboxylic acid compounds in treatment of diabetes mellitus
JP6441928B2 (ja) * 2013-11-28 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシフェニルシクロプロパンカルボン酸
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
JP2018526405A (ja) * 2015-09-09 2018-09-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング [{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用
CN105820396A (zh) 2016-04-22 2016-08-03 宁波硫华聚合物有限公司 橡胶促进剂四硫化双五亚甲基秋兰姆预分散母胶粒及其制备方法
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2020505402A5 (enExample)
JP2020514315A5 (enExample)
JP2020505400A5 (enExample)
JP2020505393A5 (enExample)
JP2020505394A5 (enExample)
JP2019535792A5 (enExample)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
JP2018526405A5 (enExample)
RU2309951C2 (ru) Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение
JP2018526352A5 (enExample)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2009532453A5 (enExample)
JP2016534084A5 (enExample)
RU2019133646A (ru) Изохинолины в качестве ингибиторов hpk1
JP2018522879A5 (enExample)
JP2019513778A5 (enExample)
JP2012513416A5 (enExample)
RU2005105683A (ru) Обладающие ингибирующим действием на vegfr-2 и vegfr-3 антраниламидопиридины
RU2019130519A (ru) 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав
RU2020102453A (ru) Фармацевтические композиции
JP2014502988A5 (enExample)
JP2017503760A5 (enExample)
JP2019504050A5 (enExample)
JP2014509600A5 (enExample)